AbCellera Biologics Inc

ABCL

Company Profile

  • Business description

    AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications. ABCL635, ABCL386, ABCL575, and ABCL635.

  • Contact

    150 W 4th Avenue
    VancouverBCV5Y 1G6
    CAN

    T: +1 604 559-9005

    E: [email protected]

    https://www.abcellera.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2026

    Employees

    562

Stocks News & Analysis

stocks

Eli Lilly receives FDA approval to add another oral GLP-1 to market

Wide moat Eli Lilly receives FDA approval for obesity pill.
stocks

Our top ASX picks in every sector

These companies are our favourite choices for investors wanting to boost Aussie equity exposure.
stocks

Which of the 3 giant AI IPOs should you buy?

OpenAI, Anthropic, and Databricks are expected to go public this year at massive valuations.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,774.90124.80-1.40%
CAC 407,962.390.000.00%
DAX 4023,168.08130.81-0.56%
Dow JONES (US)46,504.6761.07-0.13%
FTSE 10010,436.2971.500.69%
HKSE25,116.53177.50-0.70%
NASDAQ21,879.1838.230.18%
Nikkei 22553,091.74647.94-1.21%
NZX 50 Index12,902.1576.280.59%
S&P 5006,582.697.370.11%
S&P/ASX 2008,579.50105.50-1.21%
SSE Composite Index3,919.2929.27-0.74%

Market Movers